EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Erythropoietin Modulates IL-1β-Induced Chondrocyte Stress in a High-Glucose Environment in a Human Chondrocyte Cell Line

Farzaneh Motafeghi, Ehsan Ghassemi Barghi, Jafar Gholami Gharab, Nasrin Ghassemi Barghi

Osteologie · 2026-08-01 · 35 (03) · 228-237

DOI: 10.1055/a-2683-8162 ↗
AbstractBibliografische Angaben

Abstract

Abstract Osteoarthritis (OA) is a prevalent degenerative joint disease marked by cartilage degradation, pain, and impaired mobility. With rising rates of metabolic disorders such as type 2 diabetes, OA is increasingly linked to hyperglycemia. High glucose levels are known to impair chondrocyte function, accelerating cartilage breakdown and OA progression. This study investigates the potential protective role of erythropoietin (EPO) against IL-1β-induced stress in human chondrocytes under high-glucose conditions. We evaluated EPO’s effects on cell viability, oxidative stress, glucose metabolism, inflammatory mediators, and apoptosis. Human C28/I2 chondrocytes were cultured in high-glucose media and stimulated with IL-1β, with or without EPO treatment. Cell viability was assessed using the MTT assay. Oxidative stress and metabolic changes were evaluated via ROS production and glucose uptake assays. Inflammatory cytokine expression (IL-6, TNF-α) and apoptosis (TUNEL staining) were also measured. IL-1β significantly reduced cell viability, increased ROS production and glucose uptake, upregulated IL-6 and TNF-α expression, and induced apoptosis. EPO treatment effectively counteracted these effects in a dose-dependent manner, improving viability, reducing oxidative stress, normalizing glucose uptake, and decreasing inflammatory and apoptotic markers. These findings indicate that EPO mitigates IL-1β-induced chondrocyte stress in hyperglycemic conditions through modulation of oxidative, metabolic, and inflammatory pathways. EPO may offer a novel therapeutic approach for managing OA in diabetic or high-glucose-associated contexts.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →